



Inimex Pharmaceuticals Inc. and Genicon Sciences Corporation to Collaborate on Innate Immunity Research

Vancouver, B.C., Canada and San Diego, CA, USA – May 8, 2003 – Inimex Pharmaceuticals, Inc. and Genicon Sciences Corporation today announced the commencement of a research collaboration aimed at discovering new diagnostics and therapeutics for the treatment of infectious diseases.

Under the agreement, Genicon will provide reagents, instrumentation and software products that are based upon its proprietary RLS Technology to support Inimex research. Inimex will establish gene expression analysis facilities at its laboratories in British Columbia, Canada and at the laboratories of the Vaccine and Infectious Diseases Organization (VIDO), located in Saskatchewan, Canada. These facilities will be used by researchers in the Functional Pathogenomics of Mucosal Immunity (FPMI) project, a CDN\$27 million project aimed at discovering new medicines that utilize innate immunity to prevent or treat infectious diseases.

Under the agreement, Inimex will provide Genicon with an option to obtain certain rights to discoveries related to proprietary host-pathogen gene-expression data. Genicon will use this data in the development of gene-expression-based research tools and diagnostics that are optimized for use with its proprietary RLS Technology. These products would provide researchers with novel genomics tools for research in the fight against infectious diseases including bacterial infections such as *pseudomonas aeruginosa* or *E-coli* and viral infections such as *Hepatitis C* or *SARS*.

“Genicon’s RLS Technology offers superior sensitivity and reliability in comparison to currently available gene detection methods,” stated Jeffrey Bacha, President & CEO of Inimex. “This collaboration will enable us to expand our research and accelerate the commercialization of valuable intellectual property that is outside of our core business of developing new medicines for the treatment of infectious diseases.”

Patrick Mallon, President & CEO of Genicon said, “We are very pleased to be associated with Inimex and its collaborators in the FPMI project. This project will utilize our RLS Technology to delve deeply into the mechanisms of innate immunity and will provide the foundation for significant breakthroughs in the treatment of human disease.”

About Inimex Pharmaceuticals Inc.

Inimex Pharmaceuticals Inc. is focused on the development of new medicines that utilize the innate immune response to prevent or treat human disease.

To date, Inimex has identified prospective lead compounds that selectively activate elements of host innate immunity to combat infection. By enhancing innate immunity rather than acting directly against bacteria, Inimex medicines will not promote microbial drug resistance. In addition, the Inimex biology platform will generate a unique and proprietary drug discovery database and an array of targets that will provide downstream product opportunities. *For further information please visit Inimex’ website at www.inimexpharma.com.*



About Genicon Sciences Corporation

Genicon Sciences is focused on the development, manufacture and distribution of products, services, and solutions to all aspects of the life sciences market. Genicon's commercialized assay toolkits, instrumentation and software products are based upon its proprietary RLS Technology, an ultra-sensitive signal generation and detection technology.

Genicon is committed to the rapid and widespread adoption of Resonance Light Scattering (RLS) Technology in the life sciences market by providing researchers with open access to - RLS Technology – enabling the achievement of superior and cost-effective assay results. Genicon Sciences is a privately held company located in San Diego, California. *Further information can be found on Genicon Science's website at www.geniconsciences.com.*

About Vaccine and Infectious Disease Organization

VIDO is a world leader in vaccine research for the control of infectious diseases and is a wholly owned University of Saskatchewan not-for-profit institute. It operates with substantial support from the Government of Alberta and the Government of Saskatchewan as well as Government of Canada competitive grants. *For more information visit VIDO's website at www.vido.org.*

About the FPMI Project

The Functional Pathogenomics of Mucosal Immunity (FPMI) program is a three-year, \$27 million research program sponsored by Genome Canada (administered by Genome Prairie and Genome BC). The FPMI program involves a consortium of more than 70 researchers focused on understanding the mechanisms of innate immunity and how it may be safely enhanced to provide new treatment and prevention strategies for both human and animal infections. Inimex has been granted the rights to all human healthcare related discoveries arising from FPMI research.

Inimex Contact: Jeffrey Bacha, President & CEO – (604) 225-2251

Media Contact: Nancy McHarg, James Hoggan & Associates – (604) 739-7500

Genicon Contact: Janine Taylor, COO/CFO – (858) 793-0276, ext 155

Certain statements in this announcement may contain forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.